How to Choose the Right CRO for Your Phase I/II Trial

Why Early-Phase CRO Selection Matters More Than You Think

Phase I and II trials are the foundation of your clinical programme. The data generated here informs go/no-go decisions, shapes your Phase III design, and determines whether investors and regulators take your asset seriously. The CRO running this work is not a vendor — they are an extension of your development team.

Yet many sponsors approach CRO selection like a procurement exercise: issue an RFP, compare quotes, pick the lowest number. This approach consistently produces programmes that run over budget, miss timelines, and generate data that has to be explained away in later submissions.

The right CRO for early-phase work is not necessarily the biggest, the cheapest, or the one with the glossiest proposal. It is the one that brings the right combination of therapeutic expertise, operational discipline, regulatory knowledge, and genuine partnership orientation to your specific programme.

The Evaluation Framework

1. Therapeutic and Phase-Specific Experience

Phase I trials — particularly first-in-human (FIH) studies — demand a fundamentally different skill set from late-phase work. The CRO needs to understand dose escalation strategies, safety review committee operations, and the specific regulatory expectations for early safety data.

Ask specifically about:

• FIH experience: How many first-in-human studies have they conducted in the last three years? In your therapeutic area?
• Unit capabilities: Do they have in-house clinical pharmacology units, or are they brokering access to third-party sites?
• SAD/MAD design experience: Can they demonstrate expertise in single ascending dose and multiple ascending dose trial design, including adaptive approaches?
• Bioanalytical capabilities: For PK-intensive Phase I work, do they have validated bioanalytical methods and GLP-compliant laboratory partnerships?

For Phase II, the emphasis shifts toward proof-of-concept design, adaptive trial methodologies, and the ability to generate data packages robust enough to support end-of-phase meetings with regulators.

2. Team Quality and Continuity

This is where most CRO selection processes fail. The bid team — the experienced professionals who present during the pitch — is rarely the team that actually runs your study. The gap between "bid team" and "delivery team" is the single largest source of sponsor dissatisfaction.

Evaluate:

• Named team: Will they commit to named individuals in the contract, not just role descriptions?
• Staff turnover: What is their annualised turnover rate for project-level staff? Anything above 20% is a warning sign.
• Escalation pathways: When issues arise (and they will), who can make decisions? How many layers between the CRA on the ground and someone with authority?
• Sponsor references: Ask for references from the actual project team, not just the business development contact.

3. Regulatory and Geographical Expertise

If you are running a UK-based programme, your CRO needs genuine depth in MHRA and HRA requirements, not just a passing familiarity. The UK regulatory landscape has evolved significantly post-Brexit, and the practical differences in CTA submissions, ethics approvals, and pharmacovigilance reporting requirements are material.

Key questions:

• How many CTIMPs have they submitted to the MHRA in the past 24 months?
• What is their track record with HRA Ethics Committee reviews? Average time to favourable opinion?
• Do they understand the integrated Research Application System (IRAS) and the Combined Review pathway for clinical trials?
• Can they demonstrate experience with NHS site set-up, including NIHR Clinical Research Network engagement?

4. Quality Systems and Inspection Readiness

Your CRO's quality management system is not just a regulatory checkbox — it is the infrastructure that protects your data integrity. An MHRA inspection finding at your CRO becomes your problem too. Your submission is delayed, your investors ask questions, and your programme loses momentum.

Assess their QMS through:

• Inspection history: Have they been inspected by the MHRA, EMA, or FDA? What were the outcomes? Any critical findings?
• Deviation management: How do they capture, classify, and resolve deviations? What are their CAPA timelines?
• TMF standards: Do they follow the TMF Reference Model? Is the Trial Master File inspection-ready at all times, not just assembled retrospectively?
• Technology: What eTMF and CTMS platforms do they use? Are these validated systems?

5. Operational Model and Flexibility

Early-phase trials are inherently uncertain. Protocols evolve, dose levels change, timelines shift. Your CRO needs an operating model that can absorb change without treating every modification as a commercial opportunity.

Understand their model:

• Change order approach: How do they handle protocol amendments and scope changes? Is there a predefined change order process, or does every change become a negotiation?
• Functional service provider (FSP) flexibility: Can they provide specific functions (biostatistics, data management, monitoring) without requiring a full-service engagement?
• Technology integration: Can they work with your existing EDC, IWRS, or safety database, or will they require you to adopt their systems?
• AI and automation: Are they leveraging AI for document production, query management, or data review? This is increasingly relevant for operational efficiency.

6. Financial Structure and Transparency

CRO pricing for early-phase work ranges dramatically, and the headline number often conceals the true cost. A £2.5m bid from one CRO may cost you £3.2m by completion, while a £3.0m bid from another stays on budget.

Scrutinise:

• Pass-through costs: What is included in the base price, and what is billed separately? Site fees, travel expenses, lab costs, and regulatory fees can add 25–40% to the headline number.
• Milestone structure: Are payments tied to meaningful operational milestones, or are they front-loaded to de-risk the CRO's exposure?
• Change order unit rates: What are the pre-agreed rates for out-of-scope work? These rates determine your actual cost when the study deviates from plan.
• Payment terms: What are the payment schedules, and do they include holdbacks tied to deliverable quality?

The Bid Defence: Your Most Important Meeting

The bid defence is not a formality — it is the single best opportunity to assess whether a CRO can actually deliver. Approach it as a two-way working session, not a presentation.

Structure the bid defence around your programme's specific risks:

• Patient recruitment: Present your feasibility data and ask them to challenge it. A good CRO will push back on unrealistic assumptions; a desperate one will agree to anything.
• Protocol complexity: Walk through the most operationally demanding aspects of your protocol. How would they handle them? Where have they seen similar challenges before?
• Data quality: Ask to see a sample data review workflow from a comparable study. How do they manage query rates? What is their target for data entry timelines?
• Problem-solving: Describe a real scenario from your programme (a delayed site initiation, a protocol deviation, a safety signal) and ask how they would manage it.

Contracting Essentials

The Master Services Agreement and Work Order define the commercial and operational framework for your engagement. Key provisions that protect your programme:

• Performance metrics: Include KPIs for enrolment rates, data entry timelines, query resolution, and milestone achievement — with contractual consequences for sustained underperformance.
• Staffing commitments: Lock in named key personnel with contractual notification periods for team changes.
• IP and data ownership: Ensure unambiguous ownership of all trial data, documents, and intellectual property generated during the engagement.
• Audit rights: Reserve the right to conduct for-cause and routine audits of their facilities, systems, and records throughout the engagement.
• Termination provisions: Include termination for convenience with reasonable notice periods and predefined transition obligations.

Red Flags That Should End the Conversation

• Team bait-and-switch: If they will not commit to named personnel in the contract, they are planning to swap the team after signature.
• Excessive discounting: A CRO that slashes its price by 30% to win your business is either losing money (unsustainable) or planning to recover it through change orders.
• Generic proposals: If the proposal reads like a template with your company name inserted, the CRO has not engaged with your programme's specifics.
• Reluctance to provide references: If they cannot produce three recent sponsor references for comparable work, their experience claims are suspect.
• Vague quality descriptions: "We have a robust QMS" means nothing. Ask for their last inspection outcome, their deviation rate, and their CAPA closure timelines.

Making the Decision

Score each CRO against your weighted criteria before reviewing pricing. A common mistake is letting financial comparison drive the decision before evaluating operational fit. The cheapest CRO is only a bargain if they can deliver to your quality and timeline requirements.

Weight your evaluation criteria according to what matters most for your programme. For a first-in-human oncology study, therapeutic expertise and safety data quality should carry more weight than cost. For a Phase II proof-of-concept in a well-established therapeutic area, operational efficiency and data management capabilities may be more important.

The final decision should balance capability, cultural fit, and commercial terms — in that order. A CRO that understands your science, communicates honestly, and operates with discipline will save you more money in avoided problems than any discount on the headline rate.

"The CRO relationship is the most important outsourcing decision in clinical development. Get it right, and your programme gains a genuine partner. Get it wrong, and you spend your programme managing a vendor relationship instead of managing your asset."

After the Award: Setting Up for Success

Selecting the right CRO is necessary but not sufficient. The first 90 days after contract signature determine whether the relationship delivers on its promise.

• Joint kick-off: Invest in a full-day, in-person (or comprehensive virtual) kick-off meeting covering protocol walkthrough, operational logistics, communication cadences, and escalation procedures.
• Study start-up plan: Develop a detailed start-up timeline with named owners for every deliverable — regulatory submissions, site identification, contract execution, CRF design, database build.
• Communication framework: Establish regular operational calls, monthly sponsor review meetings, and documented escalation pathways. Over-communicate in the first three months.
• Performance baseline: Set measurable KPIs from day one and review them at every sponsor meeting. Early detection of underperformance is far easier to correct than problems discovered six months in.